| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial.
|
Lancet
|
2002
|
5.64
|
|
2
|
Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients.
|
J Clin Oncol
|
2007
|
4.73
|
|
3
|
Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience.
|
Int J Radiat Oncol Biol Phys
|
2004
|
3.59
|
|
4
|
Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trial.
|
BMJ
|
2006
|
3.02
|
|
5
|
Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients.
|
Cancer
|
2002
|
3.00
|
|
6
|
A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.
|
J Natl Cancer Inst
|
2005
|
2.73
|
|
7
|
Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma.
|
J Natl Cancer Inst
|
2002
|
2.61
|
|
8
|
Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma.
|
Radiother Oncol
|
2005
|
2.41
|
|
9
|
Ultra-early (within 24 hours) aneurysm treatment after subarachnoid hemorrhage.
|
World Neurosurg
|
2011
|
2.22
|
|
10
|
Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma.
|
J Clin Oncol
|
2006
|
1.92
|
|
11
|
Factors affecting workload of cancer clinical trials: results of a multicenter study of the National Cancer Institute of Canada Clinical Trials Group.
|
J Clin Oncol
|
2002
|
1.90
|
|
12
|
Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group.
|
Eur J Cancer
|
2005
|
1.80
|
|
13
|
Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival.
|
Clin Cancer Res
|
2002
|
1.74
|
|
14
|
Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer.
|
J Clin Oncol
|
2002
|
1.72
|
|
15
|
Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier?
|
J Clin Oncol
|
2003
|
1.71
|
|
16
|
Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.
|
J Clin Oncol
|
2004
|
1.65
|
|
17
|
Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group.
|
Cancer
|
2004
|
1.50
|
|
18
|
Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.
|
Cancer
|
2003
|
1.40
|
|
19
|
Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study.
|
Head Neck
|
2003
|
1.25
|
|
20
|
Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
|
Cancer
|
2002
|
1.23
|
|
21
|
Survival outcome of patients with nasopharyngeal carcinoma with first local failure: a study by the Hong Kong Nasopharyngeal Carcinoma Study Group.
|
Head Neck
|
2005
|
1.23
|
|
22
|
Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial.
|
J Clin Oncol
|
2004
|
1.20
|
|
23
|
Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA.
|
J Clin Oncol
|
2004
|
1.11
|
|
24
|
Curcumin effects on blood lipid profile in a 6-month human study.
|
Pharmacol Res
|
2007
|
1.09
|
|
25
|
A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells.
|
Invest New Drugs
|
2007
|
1.04
|
|
26
|
Dose-response relationship of nasopharyngeal carcinoma above conventional tumoricidal level: a study by the Hong Kong nasopharyngeal carcinoma study group (HKNPCSG).
|
Radiother Oncol
|
2006
|
1.04
|
|
27
|
A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy.
|
Cancer Chemother Pharmacol
|
2007
|
1.00
|
|
28
|
Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study.
|
J Clin Oncol
|
2004
|
0.98
|
|
29
|
Association of human-leukocyte-antigen class I (B*0703) and class II (DRB1*0301) genotypes with susceptibility and resistance to the development of severe acute respiratory syndrome.
|
J Infect Dis
|
2004
|
0.98
|
|
30
|
Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody.
|
Clin Chem
|
2003
|
0.96
|
|
31
|
Knowledge, perceptions, and attitudes of Hong Kong Chinese women on screening mammography and early breast cancer management.
|
Breast J
|
2005
|
0.95
|
|
32
|
Disparity of sensitivities in detection of radiation-naïve and postirradiation recurrent nasopharyngeal carcinoma of the undifferentiated type by quantitative analysis of circulating Epstein-Barr virus DNA1,2.
|
Clin Cancer Res
|
2003
|
0.95
|
|
33
|
Effects of soy isoflavone supplementation on cognitive function in Chinese postmenopausal women: a double-blind, randomized, controlled trial.
|
Menopause
|
2007
|
0.93
|
|
34
|
Comparison of CT and MR imaging for the detection of extranodal neoplastic spread in metastatic neck nodes.
|
Eur J Radiol
|
2004
|
0.93
|
|
35
|
An intensive surveillance program detected a high incidence of hepatocellular carcinoma among hepatitis B virus carriers with abnormal alpha-fetoprotein levels or abdominal ultrasonography results.
|
J Clin Oncol
|
2005
|
0.92
|
|
36
|
Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma.
|
Int J Radiat Oncol Biol Phys
|
2006
|
0.91
|
|
37
|
Quantitative measurement of post-irradiation neck fibrosis based on the young modulus: description of a new method and clinical results.
|
Cancer
|
2002
|
0.91
|
|
38
|
Correlation and prognostic significance of beta-galactoside alpha-2,6-sialyltransferase and serum monosialylated alpha-fetoprotein in hepatocellular carcinoma.
|
World J Gastroenterol
|
2005
|
0.87
|
|
39
|
Prospective validation of serum CYFRA 21-1, beta-2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy.
|
Cancer
|
2004
|
0.85
|
|
40
|
A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
|
Cancer
|
2002
|
0.84
|
|
41
|
Nasopharyngeal cancers: which method should be used to measure these irregularly shaped tumors on cross-sectional imaging?
|
Int J Radiat Oncol Biol Phys
|
2007
|
0.81
|
|
42
|
Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG).
|
Cancer Chemother Pharmacol
|
2006
|
0.80
|
|
43
|
Multinomial phase II trial designs.
|
J Clin Oncol
|
2002
|
0.78
|
|
44
|
Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer.
|
Oncology
|
2005
|
0.77
|
|
45
|
Application of wavelet-based neural network on DNA microarray data.
|
Bioinformation
|
2008
|
0.76
|
|
46
|
Adequate lymph node staging is fundamental to comparative study on resectable non-small-cell lung cancer.
|
J Clin Oncol
|
2002
|
0.75
|
|
47
|
Cross sectional survey of influenza antibodies before and during the 2009 pandemic in Shenzhen, China.
|
PLoS One
|
2013
|
0.75
|
|
48
|
A prospective study of pre-treatment cell kinetics and clinical outcome in nasopharyngeal carcinoma.
|
Radiother Oncol
|
2003
|
0.75
|
|
49
|
Is topical antimycotic treatment useful as adjuvant therapy for flexural atopic dermatitis: randomized, double-blind, controlled trial using one side of the elbow or knee as a control.
|
Int J Dermatol
|
2008
|
0.75
|